Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417530 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
A Phase 2 study, sponsored by Aura Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT04417530: Completed Phase 2 study, sponsored by Aura Biosciences.
NCT04417530 is a Phase 2 study that has completed, run by Aura Biosciences. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04417530, a Phase 2 study, has completed, sponsored by Aura Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
Primary Outcome
Adverse Events
Interventions
- DRUG AU-011
- DEVICE Suprachoroidal Microinjector
- DEVICE PDT Laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2024-04-22 |
| Phase | Phase 2 |
What the finished NCT04417530 record still lists
NCT04417530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which AU-011 is the first listed.
NCT04417530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04417530 about?
NCT04417530 is a clinical study titled "Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma". The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
What is the current status of trial NCT04417530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2020-08-05. Estimated completion is 2024-04-22.
What interventions are being tested in trial NCT04417530?
The interventions under investigation include: AU-011 (DRUG), Suprachoroidal Microinjector (DEVICE), PDT Laser (DEVICE).
Who is sponsoring clinical trial NCT04417530?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04417530's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI